Assembly Biosciences Inc (NASDAQ:ASMB) Expected to Announce Quarterly Sales of $12.54 Million

Wall Street analysts expect that Assembly Biosciences Inc (NASDAQ:ASMB) will report $12.54 million in sales for the current quarter, Zacks Investment Research reports. Four analysts have provided estimates for Assembly Biosciences’ earnings, with the lowest sales estimate coming in at $4.00 million and the highest estimate coming in at $36.04 million. Assembly Biosciences reported sales of $3.08 million during the same quarter last year, which indicates a positive year-over-year growth rate of 307.1%. The business is scheduled to issue its next quarterly earnings report on Monday, August 3rd.

On average, analysts expect that Assembly Biosciences will report full year sales of $20.36 million for the current fiscal year, with estimates ranging from $10.21 million to $40.12 million. For the next financial year, analysts forecast that the company will post sales of $15.80 million, with estimates ranging from $14.00 million to $17.60 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Assembly Biosciences.

Assembly Biosciences (NASDAQ:ASMB) last released its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.76) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.98) by $0.22. The business had revenue of $4.08 million for the quarter, compared to analyst estimates of $3.82 million. Assembly Biosciences had a negative return on equity of 45.43% and a negative net margin of 601.75%.

ASMB has been the topic of a number of research analyst reports. Zacks Investment Research lowered Assembly Biosciences from a “buy” rating to a “hold” rating in a research report on Tuesday. William Blair reiterated a “buy” rating on shares of Assembly Biosciences in a research report on Thursday. Mizuho reiterated a “buy” rating and issued a $30.00 price objective on shares of Assembly Biosciences in a research report on Friday, May 8th. ValuEngine upgraded Assembly Biosciences from a “hold” rating to a “buy” rating in a research report on Wednesday, April 8th. Finally, BidaskClub raised Assembly Biosciences from a “buy” rating to a “strong-buy” rating in a research note on Friday. Two research analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $39.75.

In other news, EVP Richard James Colonno sold 7,812 shares of the stock in a transaction on Tuesday, March 31st. The stock was sold at an average price of $15.04, for a total value of $117,492.48. Following the transaction, the executive vice president now owns 144,821 shares of the company’s stock, valued at approximately $2,178,107.84. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 12.42% of the company’s stock.

A number of institutional investors have recently modified their holdings of the stock. State Street Corp raised its stake in Assembly Biosciences by 18.4% during the 1st quarter. State Street Corp now owns 551,324 shares of the biopharmaceutical company’s stock worth $8,176,000 after buying an additional 85,622 shares during the period. Morgan Stanley raised its stake in Assembly Biosciences by 169.2% during the 1st quarter. Morgan Stanley now owns 160,050 shares of the biopharmaceutical company’s stock worth $2,374,000 after buying an additional 100,586 shares during the period. AQR Capital Management LLC acquired a new stake in shares of Assembly Biosciences in the 1st quarter valued at about $175,000. Two Sigma Advisers LP raised its stake in shares of Assembly Biosciences by 1.6% in the 1st quarter. Two Sigma Advisers LP now owns 71,200 shares of the biopharmaceutical company’s stock valued at $1,056,000 after purchasing an additional 1,100 shares during the period. Finally, Atom Investors LP acquired a new stake in shares of Assembly Biosciences in the 1st quarter valued at about $2,002,000. 88.34% of the stock is currently owned by institutional investors and hedge funds.

NASDAQ ASMB traded up $0.65 during trading hours on Friday, reaching $23.81. 166,900 shares of the company’s stock were exchanged, compared to its average volume of 261,602. The stock has a market cap of $757.85 million, a PE ratio of -6.94 and a beta of 1.26. Assembly Biosciences has a one year low of $8.13 and a one year high of $25.07. The firm has a fifty day moving average of $20.86 and a 200-day moving average of $18.82. The company has a current ratio of 12.14, a quick ratio of 12.14 and a debt-to-equity ratio of 0.03.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc operates as a clinical-stage biotechnology company in the United States. The company develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome.

Further Reading: What is a Reverse Stock Split?

Get a free copy of the Zacks research report on Assembly Biosciences (ASMB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Assembly Biosciences (NASDAQ:ASMB)

Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.